Thirteen scientists receive grant to identify new treatments, cure for psoriasis

Thirteen scientists receive grant to identify new treatments, cure for psoriasis -

Thirteen scientists received a total of $ 1.05 million in funding for the National Psoriasis Foundation projects that aim to identify new treatments and a cure for psoriasis, aian autoimmune disease that appears on the skin, affecting 7.5 million Americans, Äîand arthritis, psoriatic arthritis aian inflammatory that affects the joints and tendons, occurring in up to 30 percent of people with psoriasis.

This year, three scientists each received a two-year, 0,000 National Psoriasis Foundation Translational Grant $ to "translate" their lab results in treatments and methods for improved management of psoriatic diseases.

Translational Grant recipients and their projects are:

• Kevin Cooper, MD , of Case Western Reserve University in Cleveland received the Dr .. Alan Menter translational Grant , named in recognition of one of the specialists world leaders psoriatic diseases. Cooper will determine whether systemic psoriasis treatments can reduce the risk of cardiovascular disease.
• Riol Lorena Blanco, PhD , of Harvard Medical School will study how pain fibers cause the production of interleukin -23 (IL-23) protein related to inflammation, to find new therapies for inflammation of psoriasis.
• Michael Rosenblum, MD, Ph.D., from the University of California, San Francisco, will examine the role of a special class of regulatory T cells involved in the suppression of inflammation in people with psoriasis. It aims to discover why these cells function abnormally in psoriasis to develop treatments to repair and treat psoriasis.

In addition, 10 researchers each received a one-year, $ 75,000 grant to explore the early stage psoriatic disease. Search

beneficiaries discovery grants and their projects are:

• Rachael Clark, MD, Ph.D, Brigham & Women ' s Hospital at Harvard. University will investigate the T cells, which are involved in inflammation, which remain unhealed in psoriasis lesions and compare them to T cells in the skin of the same patient before treatment. Clark hopes to determine whether these T cells are the cause of psoriasis.
• Dan Illkovitch, MD, Ph.D., from the University of Pittsburgh Medical Center, received the Ostrow Graff Family Discovery Grant to study immune cell called myeloid suppressor cells, Äêderived, which has not been widely studied in psoriasis. It will examine the role these cells play in psoriasis, and consider whether they are affected by psoriasis.
• Jaehwan Kim, MD, PhD, Rockefeller University will develop a blood test that can predict response to treatment of a person with a biologic drug for psoriasis.
• Averil Ma, MD, from the University of California, San Francisco, will consider how to reduce the expression of the A20 gene previously implicated in the genetics of psoriasis, may increase the risk psoriasis. A20 study how functions in psoriasis could lead to treatments that are best suited for people with A20 variations.
• Pranab Mukherjee, Ph.D. , of Case Western Reserve University, received the Lozick Discovery Research Grant to study the role of the microbiome of the skin and mycobiome, or micro-organisms and fungi on the skin, in the development of psoriasis.
• Haley Naik, MD, National Institute of Dermatology branch cancer study neutrophils or cells once thought a unique link between psoriasis, heart disease and diabetes . Naik hopes to discover more about the role of these cells in psoriasis and their relationship with psoriasis severity and health risks.
• Brian POLIGONE, MD, Ph.D., from the University of Rochester School of Medicine, received the Galderma Discovery Grant to study NF-kappa B Aia transcription factor or a protein that binds to DNA, which regulates inflammation in the body. It will investigate the role of NF-kappaB in the onset of psoriasis, and explore ways to control its activity.
• Eva Reali Dr. Istituto Ortopedico Galeazzi in Milan, received the Marilyn A. Sime Discovery Grant to study the connection between cells T- pro-inflammatory in the skin of psoriasis and joint inflammation of psoriatic arthritis. Reali define the distinctive characteristics of these cells to create hopefully a biomarker, or biological sign for the development of psoriatic arthritis in patients with psoriasis.
• Jubin Ryu, MD, Ph.D., from the University of California, San Francisco, aims to develop a new method for delivering biological drugs currently administered by injection or infusion , through a patch of skin to allow localized less invasive treatment.
• Eric Sundberg, Ph.D., from the University of Maryland School of Medicine, hopes to create new molecules that suppress interleukin-36 (IL-36), a protein causing inflammation. These molecules could lead to the development of a new treatment targeted psoriasis.